MA38193B1 - Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives - Google Patents

Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Info

Publication number
MA38193B1
MA38193B1 MA38193A MA38193A MA38193B1 MA 38193 B1 MA38193 B1 MA 38193B1 MA 38193 A MA38193 A MA 38193A MA 38193 A MA38193 A MA 38193A MA 38193 B1 MA38193 B1 MA 38193B1
Authority
MA
Morocco
Prior art keywords
myeloproliferative
telomerase inhibitors
treatment
myeloproliferative disorders
disorders
Prior art date
Application number
MA38193A
Other languages
English (en)
Other versions
MA38193A1 (fr
Inventor
Monic Stuart
Stephen Kelsey
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA38193A1 publication Critical patent/MA38193A1/fr
Publication of MA38193B1 publication Critical patent/MA38193B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La présente invention concerne des procédés pour réduire la prolifération de cellules progénitrices néoplasiques et soulager des symptômes associés chez des individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que la thrombocytémie essentielle (te). La présente invention concerne en outre des procédés d'utilisation d'inhibiteurs de télomérase pour maintenir les numérations plaquettaires sanguines dans des plages relativement normales dans le sang d'individus diagnostiqués avec ou suspectés d'avoir des troubles myéloprolifératifs, tels que te.
MA38193A 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives MA38193B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Publications (2)

Publication Number Publication Date
MA38193A1 MA38193A1 (fr) 2017-12-29
MA38193B1 true MA38193B1 (fr) 2018-12-31

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45504A MA45504B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
MA38193A MA38193B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA45504A MA45504B1 (fr) 2012-12-07 2013-11-15 Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives

Country Status (37)

Country Link
EP (3) EP3456333B8 (fr)
JP (6) JP6433911B2 (fr)
KR (4) KR102662590B1 (fr)
CN (2) CN104936602B (fr)
AP (1) AP2015008504A0 (fr)
AU (4) AU2013356533B2 (fr)
BR (1) BR112015013260A2 (fr)
CA (2) CA2892907C (fr)
CL (2) CL2015001530A1 (fr)
CY (2) CY1122169T1 (fr)
DK (3) DK3456333T3 (fr)
EA (1) EA032973B1 (fr)
ES (3) ES2789176T3 (fr)
FI (2) FI3646876T3 (fr)
FR (1) FR25C1016I1 (fr)
HK (1) HK1210940A1 (fr)
HR (3) HRP20240624T1 (fr)
HU (4) HUE066402T2 (fr)
IL (3) IL317233A (fr)
LT (4) LT3456333T (fr)
MA (2) MA45504B1 (fr)
ME (1) ME03538B (fr)
MX (3) MX372753B (fr)
MY (2) MY200076A (fr)
NL (1) NL301326I2 (fr)
NZ (1) NZ708920A (fr)
PH (2) PH12019501008A1 (fr)
PL (3) PL3456333T3 (fr)
PT (3) PT2928477T (fr)
RS (2) RS59363B1 (fr)
SG (3) SG10202103341SA (fr)
SI (3) SI2928477T1 (fr)
SM (2) SMT202000328T1 (fr)
TN (1) TN2015000249A1 (fr)
UA (3) UA126015C2 (fr)
WO (1) WO2014088785A1 (fr)
ZA (3) ZA201504124B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02933B (fr) 2004-07-02 2018-04-20 Geron Corp Synthese de monomeres nucleosidiques a groupe 3'-amino protege
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
PT3065828T (pt) * 2013-11-06 2019-04-01 Mayo Found Medical Education & Res Métodos e materiais para tratar malignidades hematológicas
KR102401252B1 (ko) * 2015-04-23 2022-05-24 제론 코포레이션 다가 양이온 염 조성물을 사용한 폴리뉴클레오티드 제조의 방법
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
KR20250151565A (ko) * 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법
IL319432A (en) 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
AU2019273850B2 (en) 2018-05-25 2024-11-14 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
UA129979C2 (uk) * 2018-07-31 2025-10-01 Джерон Корпорейшн Способи ідентифікації пацієнтів з мієлофіброзом, що мають підвищену ймовірність отримати користь від лікування іметелстатом
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
EP4054594A4 (fr) * 2019-11-04 2023-12-13 Geron Corporation Utilisation d'un inhibiteur de janus kinase et d'un inhibiteur de télomérase pour le traitement de néoplasmes myéloprolifératifs
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법
US20240108734A1 (en) * 2021-01-22 2024-04-04 The Regents Of The University Of California Methods for treating and ameliorating cancer
WO2024259369A1 (fr) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions ciblant des cellules géantes dans des troubles sanguins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
JP2001507229A (ja) 1996-12-20 2001-06-05 ジェロン コーポレイション テロメラーゼのｒｎａ成分を検出および阻害するための方法
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP2007525414A (ja) * 2003-01-31 2007-09-06 ジェシー エル エス オウ スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (fr) 2004-07-02 2018-04-20 Geron Corp Synthese de monomeres nucleosidiques a groupe 3'-amino protege
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (fr) * 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP4474480A2 (fr) * 2006-10-30 2024-12-11 Geron Corporation Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
AU2013356533A1 (en) 2014-06-12
SG11201504383TA (en) 2015-07-30
JP2022050537A (ja) 2022-03-30
CY1122169T1 (el) 2020-11-25
IL280144A (en) 2021-03-01
CY1123206T1 (el) 2021-10-29
NZ708920A (en) 2020-08-28
SG10202103341SA (en) 2021-05-28
EA032973B1 (ru) 2019-08-30
IL280144B1 (en) 2025-01-01
JP2016504307A (ja) 2016-02-12
EP3456333B8 (fr) 2020-05-13
CL2015001530A1 (es) 2016-03-28
LT3646876T (lt) 2024-05-10
FIC20250019I1 (fi) 2025-05-07
SMT202000328T1 (it) 2020-07-08
ES2982897T3 (es) 2024-10-18
JP2022179684A (ja) 2022-12-02
KR20230028590A (ko) 2023-02-28
RS60401B1 (sr) 2020-07-31
MX2015007169A (es) 2016-03-31
HK1212226A1 (en) 2016-06-10
PT3646876T (pt) 2024-05-15
EP3456333A1 (fr) 2019-03-20
MX372753B (es) 2020-06-26
IL239266B (en) 2019-11-28
KR20250114449A (ko) 2025-07-29
PL2928477T3 (pl) 2020-03-31
ZA201504124B (en) 2017-05-31
LT2928477T (lt) 2019-10-10
NL301326I2 (nl) 2025-07-31
IL239266A0 (en) 2015-07-30
KR102294819B1 (ko) 2021-09-01
SMT201900567T1 (it) 2019-11-13
SI2928477T1 (sl) 2019-11-29
AU2020267142A1 (en) 2020-12-03
MX2020003276A (es) 2020-07-20
RS59363B1 (sr) 2019-11-29
EA201590878A1 (ru) 2016-04-29
MA45504B1 (fr) 2021-10-29
AU2024203138A1 (en) 2024-07-25
MA45504A1 (fr) 2020-05-29
SI3456333T1 (sl) 2020-10-30
CL2017002156A1 (es) 2018-05-04
IL280144B2 (en) 2025-05-01
CA2892907A1 (fr) 2014-06-12
DK3646876T3 (da) 2024-05-06
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
ES2744790T3 (es) 2020-02-26
JP2018035196A (ja) 2018-03-08
IL317233A (en) 2025-01-01
UA128370C2 (uk) 2024-06-26
MY200076A (en) 2023-12-06
MX2022015437A (es) 2023-01-11
ZA202108991B (en) 2023-05-31
KR102662590B1 (ko) 2024-05-03
LT3456333T (lt) 2020-06-25
EP2928477A4 (fr) 2016-09-21
JP6998191B2 (ja) 2022-02-04
MA38193A1 (fr) 2017-12-29
AU2013356533B2 (en) 2018-09-27
CN104936602A (zh) 2015-09-23
KR20210107906A (ko) 2021-09-01
CN111617252A (zh) 2020-09-04
AP2015008504A0 (en) 2015-06-30
CA2892907C (fr) 2023-03-21
UA126015C2 (uk) 2022-08-03
JP6433911B2 (ja) 2018-12-05
KR20150091130A (ko) 2015-08-07
CA3188494A1 (fr) 2014-06-12
EP2928477B1 (fr) 2019-07-24
PL3646876T3 (pl) 2024-07-22
ES2789176T3 (es) 2020-10-26
ME03538B (fr) 2020-07-20
PT3456333T (pt) 2020-06-01
HRP20240624T1 (hr) 2024-08-02
PT2928477T (pt) 2019-10-25
JP2025109842A (ja) 2025-07-25
HRP20191784T1 (hr) 2019-12-27
PH12015501282B1 (en) 2015-08-24
TN2015000249A1 (en) 2016-10-03
HK1210940A1 (zh) 2016-05-13
PL3456333T3 (pl) 2020-09-21
EP3456333B1 (fr) 2020-04-01
NZ748134A (en) 2020-10-30
EP2928477A1 (fr) 2015-10-14
AU2020267142B2 (en) 2024-05-16
WO2014088785A1 (fr) 2014-06-12
JP7288098B2 (ja) 2023-06-06
WO2014088785A8 (fr) 2015-07-16
HUE066402T2 (hu) 2024-07-28
BR112015013260A2 (pt) 2018-02-06
EP3646876B1 (fr) 2024-02-14
UA117116C2 (uk) 2018-06-25
HUE049858T2 (hu) 2020-11-30
LTPA2025517I1 (fr) 2025-05-26
ZA202212327B (en) 2025-03-26
DK2928477T3 (da) 2019-10-07
EP3646876A1 (fr) 2020-05-06
HUS2500019I1 (hu) 2025-05-28
PH12019501008A1 (en) 2022-11-14
MY180634A (en) 2020-12-03
FI3646876T3 (fi) 2024-05-14
FR25C1016I1 (fr) 2025-06-20
AU2018282364A1 (en) 2019-05-23
AU2020267142C1 (en) 2024-08-08
SI3646876T1 (sl) 2024-07-31
PH12015501282A1 (en) 2015-08-24
JP2020041001A (ja) 2020-03-19
SG10201802926XA (en) 2018-05-30
DK3456333T3 (da) 2020-05-18
CN104936602B (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
MA38193B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
WO2014039513A3 (fr) Inhibition de la diacylglycérol kinase pour augmenter le transfert de lymphocyte t adoptif
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MA38925A1 (fr) Dérivés de phénylalanine substitués
MX358589B (es) Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
EP4541421A3 (fr) Nalméfène pour la réduction de la consommation d'alcool dans des populations cibles spécifiques
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
MA54889B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
BR112015024516A2 (pt) métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação
WO2012009640A3 (fr) Appauvrissement en cellules b pour traiter des lésions du système nerveux central et procédés et utilisations connexes
EA201990799A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
FR3011468B1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
СВЕТУНЬКОВ et al. ON THE DIAGNOSIS OF LEVEL OF SOCIAL AND ECONOMIC DEVELOPMENT OF REGIONS
Ostrovskiy et al. The issues of management of public purchases of medical production
MA35029B1 (fr) Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
MA39100A1 (fr) Compositions et procédés pour réduire des événements cardiovasculaires indésirables majeurs
UA107707C2 (en) The use of inhibitors of bruton's tyrosine kinase (btk)
AU334566S (en) Visor for sunglasses and or spectacles